Showing results (261-270 of 366) with videos related to
Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 StudyJacob Sands, Myung-Ju Ahn, Aaron Lisberg, et al.The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2026
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung CancerSolange Peters, Roy Herbst, Hidehito Horinouchi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2022
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)Sai-Hong Ignatius Ou, Makoto Nishio, Myung-Ju Ahn, et al.The Oncologist|April 13, 2019
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung CancerLecia V Sequist, Jhanelle Elaine Gray, Wael A Harb, et al.NPJ Precision Oncology|April 29, 2021
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survivalVladimir Lazar, Shai Magidi, Nicolas Girard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients WithGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.The Lancet. Oncology|November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2021
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L TrialD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.Pageof 37